<DOC>
	<DOCNO>NCT01372644</DOCNO>
	<brief_summary>Atypical ductal hyperplasia ( ADH ) atypical lobular hyperplasia ( ALH ) increase breast cancer risk . In post menopausal woman , SERMS standard chemopreventive agent . The investigator previously show insulin-like growth factor-I ( IGF-I ) require permit estrogen ( E2 ) progesterone action mammary gland , novel somatostatin analog , SOM230 , inhibit IGF-I action prevent E2 action mammary gland . It reduce cell proliferation increase apoptosis ( cell death ) rat mammary gland . This study design determine whether woman high risk breast cancer respond SOM230 way rat . Methods : Women atypical ductal hyperplasia lobular carcinoma in-situ core biopsy treat 9.5 day SOM230 ( 600mcg BID ) . Surgical excision perform day 10 . Sections examine SOM230 treatment cell proliferation ( Ki67 ) apoptosis ( TUNEL ) . Serum IGF-I , fast glucose , insulin , HbA1C measure anticipation change .</brief_summary>
	<brief_title>Breast Cancer Chemoprevention SOM230 , IGF-I Action Inhibitor : A Proof Principle Trial</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<criteria>Inclusion Criteria Over 21 year age Must sign inform consent , witness , date prior entry The participant increase risk develop breast cancer may include ; Atypical Ductal Hyperplasia ( ADH ) , Lobular Carcinoma situ ( LCIS ) , and/or Atypical Lobular Hyperplasia ( ALH ) Performance Status : ECOG 01 unless mobility limit chronic physical handicap No clinical evidence malignancy ( except Basal Cell carcinoma ) Complete blood count , differential platelet count must within normal limit ( WNL ) verify study chair related condition interfere normal health status Adequate hepatic renal function ( must WNL verified study chair related condition interfere normal health status ) Normal fast glucose No history diabetes Medically Psychologically able comply study requirement Accessible Follow Exclusion Criteria Less 21 year age Known invasive breast cancer type Bilateral prophylactic mastectomy Prior malignancy type occur less 5 year previously , except basal squamous cell carcinoma skin carcinoma situ cervix Existing nonmalignant disease would preclude administration SOM230 Pregnancy : All subject beta human chorionic gonadotropin ( bhCG ) serum pregnancy test rule pregnancy , history also take make certain recent sexual exposure put risk pregnancy . If second serum pregnancy test do . Volunteers ask use barrier contraception study . Tamoxifen preventive measure within 6 month Serious Psychiatric condition addictive disorder Diabetes elevate fast blood sugar Inability inject medication test finger stick glucose Symptomatic gallstone know gall bladder disease History cholecystitis without cholecystectomy Electrolyte abnormality ( particularly hypokalemia hypomagnesemia ) QT relate exclusion criterion QTcF screen &gt; 450 msec . History syncope family history idiopathic sudden death . Sustained clinically significant cardiac arrhythmia . Risk factor Torsades de Pointes hypokalemia , hypomagnesemia , cardiac failure , clinically significant/symptomatic bradycardia , highgrade AV block . Concomitant disease ( ) could prolong QT autonomic neuropathy ( cause diabetes , Parkinson 's disease ) , HIV , cirrhosis , uncontrolled hypothyroidism cardiac failure Concomitant medication ( ) know increase QT interval .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>